Untitled

 In the highly competitive and strictly regulated generic drug development landscape, securing the right Reference Listed Drug (RLD) or clinical trial comparator is one of the most critical steps. Whether you are conducting bioequivalence (BE) studies, pre-clinical evaluations, or phase-based clinical trials, the integrity, timeliness, and traceability of your reference drug supply lay the foundation for regulatory approval.

Neunco stands out as a global leader in clinical trial supply management and reference drug sourcing, offering pharmaceutical developers in India and worldwide an end-to-end, seamless partner network.

The Strategic Importance of Precision RLD Sourcing

An RLD serves as the benchmark against which generic formulations prove bioequivalence in quality, performance, and safety. However, acquiring authentic RLDs and comparators presents significant operational hurdles:

Single vs. Multi-Batch Requirements: Trials often demand specific batch numbers or multi-batch lots to test variable parameters.

Tight Expiry Timelines: Bioequivalence studies require products with sufficiently long shelf lives to prevent expensive delays.

Country-Specific Regulatory Nuances: Sourcing an RLD directly from a target market—such as the US, EU, or East Asia—demands compliance with local health authorities.

Cold-Chain Integrity: A single temperature excursion can render an entire shipment unusable.

Neunco mitigates these risks by combining deep domain expertise, a robust global network, and verified logistics.

Why Neunco is Your Trusted Partner for RLD and Comparator Sourcing

Neunco simplifies generic drug development and clinical trial supply through tailored, transparent, and compliant sourcing solutions.

1. Extensive Global Reach & Country-Specific Sourcing

Neunco’s procurement footprint reaches far beyond local borders. Neunco sources and distributes reference drugs across major global markets, including:

North America: USA, Canada

Europe: EU Member States

Asia-Pacific: South East Asia, Japan, South Korea, Australia

Latin America

Whether your trial demands a single-country source or one-to-many pack deliveries across multiple regions, Neunco fulfills exact regulatory criteria.

2. State-of-the-Art GDP Certified Warehousing

Proper storage maintains drug integrity throughout the lifecycle of a study. Neunco operates verified storage facilities equipped with over 20,000 pallet positions across ambient, refrigerated ($2^\circ\text{C} - 8^\circ\text{C}$), and frozen conditions:

EU GDP-Certified Facility: Located in the Netherlands.

Licensed Distribution Center: Situated in New Jersey, USA.

These certified spaces can accommodate everything from a single pack to hundreds of thousands of units, offering inventory storage across the entire trial duration for rapid dispatch.

3. Tailored, Customer-Centric Procurement

Neunco recognizes that no two clinical studies have the same parameters. Sourcing models are customized to meet specific demands:

Sourcing in single or multi-batch lots

Procurement of drugs with extended expiry dates

Locating specific manufacturer batch numbers

Customized pack sizes and lot configurations

4. End-to-End Temperature-Controlled Supply Chain

Flawless logistics guarantee that sensitive drugs arrive On Time and In Full (OTIF). Holding Wholesale Distribution Authorizations (WDA), Neunco ensures:

Fully traceable supply chains from certified origin to destination.

Specialized temperature-monitored vehicles for last-mile delivery.

Advanced cold-chain protocols for international air transport.

Neunco's Structured 4-Step Sourcing Process

Neunco enforces a transparent, risk-assessed workflow across every project to maintain clinical timelines:[1. Understand] ➔ [2. Scrutinize] ➔ [3. Assess] ➔ [4. Propose]

Understanding: Deep analysis of trial protocols, specific batch requests, target jurisdiction requirements, and timelines.

Scrutinizing: Screening global supply networks to identify optimal procurement avenues.

Assessing: Evaluating regulatory risks, lead times, and cold-chain constraints to prevent bottlenecks.

Proposing: Delivering a transparent strategy optimized for cost, compliance, and swift execution.

Streamline Your Clinical Trial Supply Chain with Neunco

Securing high-quality Reference Listed Drugs and comparators shouldn't be the roadblock that delays your generic formulation or clinical study. Partnering with Neunco gives your clinical trials the backing of a transparent, GDP-compliant, and truly global supply network.

Looking to source RLDs or Comparators for your upcoming studies?

Explore Neunco's Sourcing Capabilities: Neunco Clinical Trial Supply & RLD Sourcing

 In the modern pharmaceutical industry, bringing a life-saving drug from the laboratory to the patient requires a delicate balance of cutting-edge research, strict regulatory oversight, and scalable manufacturing. At the heart of every effective medication lies its Active Pharmaceutical Ingredient (API)—the biologically active component responsible for delivering the intended therapeutic effect.

Developing and scaling API production in-house requires immense capital investment, specialized facilities, and specialized technical expertise. To optimize costs and accelerate commercial timelines, pharmaceutical companies increasingly rely on API Contract Manufacturing.

What is API Contract Manufacturing?

API contract manufacturing involves outsourcing the synthesis, scale-up, and production of active pharmaceutical ingredients to specialized third-party organizations—such as Contract Manufacturing Organizations (CMOs) or Contract Development and Manufacturing Organizations (CDMOs).

Rather than maintaining costly internal infrastructure for every molecule in a pipeline, drug developers partner with contract manufacturers to handle complex chemical synthesis, scale-up, quality control, and compliance with global Good Manufacturing Practices (GMP).

Key Strategic Benefits of Outsourcing API Production

Outsourcing API manufacturing has evolved from a simple cost-reduction tactic into a core strategic driver for pharmaceutical companies of all sizes.

1. Capital Efficiency & Lower Operational Costs

Setting up state-of-the-art facilities with specialized containment, reaction vessels, and analytical labs demands tens of millions of dollars in capital expenditure (CapEx). Partnering with an established contract manufacturer eliminates these fixed overheads, allowing pharmaceutical companies to convert fixed costs into variable, predictable operating expenditures.

2. Access to Advanced Technologies & Specialized Expertise

Modern APIs—especially high-potency APIs (HPAPIs), complex synthetics, and biologics—require niche technologies such as cryo-reactors, continuous flow chemistry, or specialized isolation equipment. Contract manufacturers invest continuously in late-stage tech platforms and employ teams of experienced chemists, process engineers, and analytical scientists.

3. Scalable Efficiency & Faster Time-to-Market

From clinical trial material (CTM) supply to commercial-scale batch production, contract manufacturing enables seamless scaling. Established partners have the infrastructure and regulatory filings ready to rapidly adapt to shifting market demand, helping companies launch therapies significantly faster.

4. Regulatory Navigability & Compliance Assurance

Navigating regulatory authorities—such as the US FDA, EMA, or PMDA—requires meticulous documentation, validation, and adherence to evolving cGMP standards. Specialized contract manufacturers maintain audit-ready facilities and deep regulatory track records, reducing the risk of clinical delays or regulatory rejections.

5. Laser Focus on Core Competencies

Delegating chemical synthesis and batch manufacturing allows pharmaceutical leadership to focus on what they do best: drug discovery, clinical trial management, strategic licensing, and commercial distribution.

Challenges in API Sourcing—and How to Overcome Them

While the benefits are substantial, outsourcing API production introduces operational and strategic challenges that require diligent management:

Quality Control & Scale-Up Impurities: Scaling a chemical synthesis from benchtop to commercial reactors can introduce unforeseen impurities or reaction variations. Partnering with facilities that feature robust analytical R&D and strict batch testing protocols is essential to maintain batch-to-batch consistency.

Intellectual Property (IP) Protection: Safeguarding proprietary chemical routes, patents, and manufacturing know-how requires rigorous legal protections, non-disclosure agreements, and clear IP frameworks.

Supply Chain Continuity: Disruptions in raw material supply or international shipping can stall production. Incorporating modern supply chain forecasting, multi-sourcing strategies, and real-time tracking mitigates inventory risk.

How Neunco Streamlines Your API Manufacturing Journey

Finding the right contract manufacturing partner is not just about locating a facility—it is about matching your molecule's unique specifications, regulatory targets, and scale requirements with a thoroughly vetted supplier.

As a trusted global pharmaceutical consultancy, Neunco bridges the gap between pharmaceutical innovators and top-tier contract manufacturing partners:

Tailored Matching & Strategic Sourcing: We evaluate your specific drug profile, target markets, and budget constraints to match you with verified CMO/CDMO partners across our extensive global network.

End-to-End Regulatory Support: Neunco assists in navigating complex GMP landscapes, clinical trial supply sourcing, and licensing requirements to ensure smooth market entry.

Risk Mitigation: From protecting your confidential intellectual property to evaluating supplier quality standards, Neunco guides you through the partner evaluation process with precision and transparency.

Transform Your API Strategy with Neunco

Whether you are seeking clinical-stage API manufacturing for an upcoming trial or scaling commercial production for global distribution, choosing the right partner is critical to your market success.

Ready to streamline your API production and eliminate supply chain guesswork?

 In modern clinical development, securing the right commercial drugs for comparison is no longer a simple transactional purchase. As clinical trial designs become more complex—driven by oncology breakthroughs, personalized medicine, and global multi-center protocols—sourcing Reference Listed Drugs (RLD) and investigational comparators has become one of the highest-risk phases in drug development.

Relying on traditional, reactive procurement models often leads to stockouts, regulatory delays, batch inconsistencies, and inflated costs. To protect trial timelines and patient outcomes, life sciences companies must evolve from basic purchasing to a resilient, strategic global comparator sourcing model.

Here is how building a forward-looking comparator sourcing strategy drives clinical trial excellence—and how Neunco empowers biopharmaceutical innovators to achieve it.

The Hidden Complexity of Modern Comparator Sourcing

Sourcing comparator drugs sounds straightforward on paper: buy commercial products and deliver them to clinical sites. In practice, clinical supply chain leaders face a web of global bottlenecks:

Market Supply Scarcity & Allocation Controls: Pharmaceutical manufacturers tightly monitor commercial volume to prevent parallel trading, making single-source bulk procurement difficult.

Batch Consistency & Expiry Management: Complex Phase II and Phase III trials require large quantities of single-lot comparators with long shelf lives to preserve protocol integrity.

Strict Cold Chain & Regulatory Nuances: Sourcing across different geographies requires navigating distinct regulatory bodies (FDA, EMA, MHRA) alongside stringent GDP (Good Distribution Practice) compliance for temperature-sensitive biologics.

Region-Specific Packaging & Labeling: Local language requirements, blindings, and country-specific patient information leaflets (PILs) add operational friction.

When comparator sourcing is treated as an afterthought, a single supply bottleneck can halt site activation, derail patient dosing schedules, and cost millions in delayed market launch.

4 Pillars of a Resilient Global Sourcing Strategy

Transforming comparator procurement into a strategic asset requires four foundational practices:

1. Shift from Reactive Buying to Early Sourcing Strategy

Early collaboration between protocol design teams and sourcing partners prevents costly re-designs later. Evaluating market availability, lead times, and regulatory constraints during protocol design ensures that selected comparators can actually be procured at scale.

2. Multi-Region Sourcing Networks

Relying on a single distributor or geographic market introduces systemic vulnerability. Resilient supply chains utilize dual-sourcing models—leveraging vetted global networks across North America, Europe, and Asia-Pacific to pivot swiftly if local supply fails.

3. Tailored & Agile Logistics Solutions

Modern clinical trials rarely follow static pathways. From Just-In-Time (JIT) supply models to Direct-to-Patient (DTP) delivery, flexible packaging and local depot networks ensure investigational products reach trial sites safely without excess inventory waste.

4. Robust Regulatory & Quality Compliance

Every link in the chain—from initial vendor qualification to final site delivery—must strictly adhere to EU-GDP, US FDA, and local country regulations. Complete traceability, verified documentation, and audited warehousing are mandatory to pass regulatory scrutiny.

How Neunco Powers Clinical Trial Excellence

At Neunco, we go beyond traditional brokerage. We serve as a strategic clinical trial supply partner, building end-to-end resilience into every stage of your drug development journey.

Strategic Global Infrastructure

Neunco operates state-of-the-art hubs placed in major pharmaceutical regions:

EU-GDP Certified Hub: Our warehouse storage and distribution center in the Netherlands offers seamless access to European and global clinical trial sites under strict GDP standards.

USA-WDA Compliant Hub: Our strategic warehouse facility in New Jersey, USA, serves as a dedicated footprint for North American trials and cold-chain management.

Integrated Indian & Global Network: Strong local market connections allow us to source hard-to-find APIs, RLDs, and commercial supplies directly from vetted manufacturers.

Customized Clinical Trial Supply Solutions

No two clinical trials are identical. Neunco provides customized, flexible solutions tailored to your protocol size and scope:

Low-Volume & Niche Sourcing: Specialized supply models for rare disease, oncology, and targeted biologic studies.

End-to-End Comparator & RLD Sourcing: Directly procuring single or multi-lot commercial batches with guaranteed shelf-life stability.

Clinical Packaging & Relabeling: Blinding, local language packaging, and kitting tailored to country-specific regulatory protocols.

Integrated CRO, CMO & CDMO Ecosystem: Connecting sponsor companies with high-performing development and manufacturing partners to accelerate product lifecycle execution.

Transform Your Clinical Sourcing Strategy with Neunco

Trial delays caused by comparator stockouts or regulatory friction are preventable. By partnering with a dedicated strategic partner who combines global regulatory knowledge with flexible logistics, life sciences companies can protect their trial timelines and keep focus on patient outcomes.

Whether you need low-volume comparator drug sourcing, JIT clinical packaging, or EU/US depot support, Neunco delivers the reliability, speed, and quality your clinical trials demand.

Ready to Elevate Your Clinical Supply Chain?

 In today's fast-paced pharmaceutical landscape, taking a drug candidate or formulation from the laboratory to global commercialization is one of the most resource-intensive challenges a manufacturer can face. Developing high-quality formulations, compiling robust regulatory dossiers, and conducting bioequivalence studies demand substantial capital and expertise.

However, bringing a product to market in multiple international jurisdictions doesn't mean you have to build a local sales force, navigate unfamiliar regulatory frameworks, or absorb all the commercial risks on your own.

This is where Pharma Out-Licensing becomes a game-changer — and where Neunco serves as your trusted global partner.

What is Pharma Out-Licensing?

Out-licensing occurs when a drug manufacturer, developer, or IP holder grants rights to an external partner — such as an investor, marketing firm, or regional distributor — to commercialize, distribute, and market their pharmaceutical product in specific target regions.

By out-licensing your ready-to-file dossiers, generic formulations, or specialized technologies, your business can:

Monetize existing assets without heavy upfront capital expenditure in new territories.

Accelerate market entry by leveraging established local distribution channels.

Generate predictable, recurring revenue streams while focusing on core R&D and manufacturing competencies.

The Challenges of Global Out-Licensing

While the rewards of global expansion are clear, finding the right commercial partner can be daunting. Drug developers frequently encounter:

Regulatory Complexity: Divergent requirements across key regions like the US FDA, European EMA, Latin America, CIS, Southeast Asia, Africa, and the Middle East.

Partner Vetting & Due Diligence: Identifying credible, reliable partners who possess genuine market reach and financial stability.

Project & Tech Transfer Friction: Managing seamless handoffs of technical dossiers, bio-study data, and manufacturing processes.

Without a structured licensing framework, valuable intellectual property can remain underutilized or bogged down in prolonged negotiations.

How Neunco Elevates Your Out-Licensing Strategy

At Neunco, we specialize in connecting pharmaceutical manufacturers with established commercialization partners, investors, and regional leaders across the globe. We act as an active growth catalyst throughout the entire licensing lifecycle.

Here is how Neunco’s structured out-licensing services empower your pharmaceutical business:

1. Access to a Vetted Global Partner Network

Expanding into international markets requires deep local intelligence. Neunco maintains an active international network covering key markets, including the USA, EU, Latin America, CIS, Southeast Asia, Africa, and the Middle East. We connect you with pre-vetted, recurring commercial partners who are actively seeking ready-to-file and approved dossiers.

2. Rapid Pathways via Ready-to-File Dossiers & Tech Transfer

First-mover advantage is essential in the generics and specialized pharma spaces. Neunco facilitates the licensing and acquisition of ready-to-file dossiers, technology transfer packages, and bio-study-ready dossiers created to comply with target market regulations (including USA, Europe, Canada, Australia, and Japan).

3. Integrated CRO, CMO, and CDMO Ecosystem

Licensing rarely exists in isolation. Beyond deal structuring, Neunco connects partners with world-class contract service providers:

CROs for streamlined clinical research and R&D support.

CMOs for scalable, compliant manufacturing capabilities.

CDMOs for end-to-end solutions from development to commercialization.

4. End-to-End Project Management & Due Diligence

A successful agreement requires absolute clarity and transparency. Neunco’s team performs rigorous due diligence upfront to ensure a strong commercial match. From initial contact to contract execution and ongoing tech transfer, our project managers provide transparent communication and continuous support.

Why Partner with Neunco for Out-Licensing?

"Our mission is simple: to transform complex global licensing into a predictable, high-value growth engine for your pharmaceutical business."

Maximized ROI on R&D: Monetize your existing portfolio and dossier library across multiple non-competing geographies.

Reduced Time-to-Market: Leverage pre-analyzed market databases and verified commercial partners to bypass prolonged market setup delays.

Complete Transparency: Comprehensive project management ensures every step — from initial dossier evaluation to commercial launch — stays on schedule and fully compliant.

Ready to Expand Your Global Footprint?

Whether you are looking to out-license approved generic dossiers, commercialize specialized therapeutic formulations, or access new international markets, Neunco has the network and expertise to take your licensing strategy to the next level.

In the modern pharmaceutical landscape, bringing an effective therapy from the lab to patients requires balancing complex chemical synthesis, rigorous regulatory standards, and tight cost controls. At the core of every drug product—whether a tablet, capsule, injectable vial, or cream—lies its Active Pharmaceutical Ingredient (API).

While the API is the biologically active element responsible for producing the intended therapeutic outcome, producing it in-house demands massive capital expenditure, specialized facilities, and niche technical talent. To stay competitive and agile, pharmaceutical companies increasingly partner with specialized third parties—Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs)—to handle API contract manufacturing.

What is API Contract Manufacturing?

API contract manufacturing is the strategic outsourcing of active raw material development, synthesis, and commercial production to an external specialized drug manufacturer.

Rather than building and maintaining costly infrastructure for every new molecule, drug developers collaborate with established manufacturing partners equipped with validated facilities, state-of-the-art equipment, and full regulatory clearance.

Core Strategic Advantages of API Outsourcing

1. Significant Cost Optimization

Developing and synthesizing specialized active ingredients internally requires substantial capital investments in cleanrooms, specialized chemical reactors, and analytical testing laboratories. Contracting API production transforms these heavy fixed overheads into manageable variable costs, allowing companies to reallocate capital toward R&D and market expansion.

2. Rapid Scalability & Speed-to-Market

From pilot-scale batches for clinical trials to large-scale commercial runs, CDMOs possess the operational bandwidth to scale up rapidly. Their existing infrastructure and established batch processes significantly accelerate development timelines.

3. Immediate Access to Technical Expertise

Modern APIs often involve multi-step chemical synthesis, highly potent compounds (HPAPIs), or sensitive biological processes. Partnering with a specialized manufacturer grants instant access to highly skilled chemical engineers, formulation scientists, and advanced automation technologies.

4. Direct Navigation of Regulatory Frameworks

API manufacturing is subject to stringent global regulations, including Good Manufacturing Practices (cGMP), ICH Q7 guidelines, and oversight from regulatory bodies like the FDA and EMA. Top-tier contract manufacturers maintain pre-validated systems, comprehensive documentation, and audit-ready operations.

Critical Challenges & Risk Management

While outsourcing offers tremendous advantages, delegating API synthesis introduces complex operational risks that require active oversight:

Quality Control & Impurity Profiles: Scaling chemical synthesis from lab scale to commercial scale can inadvertently introduce unforeseen impurities or alter batch consistency. Strict analytical testing and process validation are essential.

IP & Confidentiality Protection: Protecting proprietary synthesis routes and chemical patents requires robust legal agreements and security protocols across foreign jurisdictions.

Supply Chain & Temperature Stability: APIs are often highly sensitive to environmental factors. Maintaining strict temperature calibration, cold-chain integrity, and continuous supply traceability is vital to prevent degradation.

How Neunco Simplifies Your API Manufacturing Journey

Finding a contract manufacturer is easy—finding the right partner who aligns with your specific therapeutic molecule, batch size, target markets, and quality benchmarks is much harder.

As a specialized pharmaceutical consultancy, Neunco bridges this critical gap. We partner with global pharma developers to streamline and secure their API sourcing and manufacturing strategies:

Tailored Manufacturer Vetting: We leverage our global network and database to evaluate third-party contract manufacturers against international cGMP standards, regulatory track records, and technical capabilities.

End-to-End Compliance Support: We guide your team through regulatory frameworks, supplier quality audits, and safety guidelines (ICH Q7, Q8, Q9, Q10) to minimize compliance risk before production starts.

Optimized Sourcing & Strategic Alignment: From clinical trial batches to commercial distribution, we align your drug requirements with flexible, high-standard manufacturing partners to protect your bottom line and supply integrity.

Ready to Streamline Your API Supply Chain?

Whether you are scaling up a molecule for upcoming clinical trials or looking to optimize commercial API production, partnering with the right CDMO network is key to long-term success.

Developing a breakthrough drug formulation or bringing a generic therapy to completion is a massive achievement. But for many pharmaceutical manufacturers and biotech innovators, the hardest challenge begins after the lab work is done: commercializing the asset globally without overextending internal resources.

Entering new geographic markets independently requires substantial capital, localized regulatory expertise, and established sales infrastructure. This is where pharma out-licensing becomes a primary engine of growth.

By out-licensing your products, dossiers, or technologies to established commercial partners, you can monetize your IP, secure reliable royalty streams, and expand your global footprint—all while mitigating cross-border operational risks.

Here is how Neunco acts as the strategic catalyst in your out-licensing journey.

What Is Pharma Out-Licensing (and Why Is It Critical Now)?

Out-licensing occurs when a drug developer or manufacturer transfers the marketing and commercialization rights of a pharmaceutical asset—such as an active formulation, ready-to-file dossier, or approved product—to a partner (the licensee or Marketing Authorization Holder) in exchange for upfront payments, milestone fees, and royalties.

In today's pharmaceutical landscape, the traditional model of doing everything in-house—from R&D to worldwide marketing—is often too slow and capital-intensive.

Out-licensing solves this by allowing companies to:

Accelerate Time-to-Market: Leverage partners who already possess local regulatory relationships and distribution networks.

Unlock Unused Assets: Monetize dossiers, technology platforms, or niche therapeutic assets that don't fit your core geographic focus.

Maximize ROI: Generate recurring revenue through milestone payments and royalties while shifting commercialization costs to the licensee.

How Neunco Elevates Your Out-Licensing Strategy

Finding a partner is easy; finding the right partner—one that aligns with your financial goals, compliance standards, and market priorities—is much harder.

Neunco bridges this gap by offering end-to-end, structured licensing consultancy tailored to the pharmaceutical industry. Rather than simply providing contact lists, Neunco serves as an active commercial architect for your assets.

1. Global Reach Across High-Growth & Regulated Markets

Navigating regional regulatory variances can quickly derail deal momentum. Neunco’s established network spans key global regions, including:

Regulated Markets: USA, EU, Canada, Australia, and Japan.

Emerging & Semi-Regulated Markets: Latin America, Southeast Asia, CIS, Middle East, and Africa.

Whether you are looking to enter mature Western markets or capture market share in rapid-growth regions, Neunco matches your portfolio with verified commercialization partners in target territories.

2. Ready-to-File Dossiers & First-Mover Advantage

Speed is everything in competitive therapeutic areas. Neunco maintains a pre-analyzed database of ready-to-file and approved dossiers, as well as dossiers ready for bio-equivalence (BE) studies.

By facilitating out-licensing agreements for these ready assets, Neunco helps licensors grant immediate commercialization pathways to partners, securing a crucial first-mover advantage and maximizing long-term profitability.

3. Rigorous Due Diligence & Strategic Matchmaking

A failed licensing deal costs time and reputational capital. Neunco performs thorough due diligence on both sides of the deal:

Evaluating the financial stability and market track record of prospective licensees.

Verifying that dossiers comply with local regulatory standards (such as US FDA, EMA, or regional MOH guidelines).

Ensuring cultural, strategic, and financial alignment before deal execution.

4. Comprehensive End-to-End Project Management

Neunco stays involved well beyond initial introductions. Their team manages the entire deal life cycle:

Strategic Positioning: Framing your asset’s value proposition for target investors or commercial partners.

Tech Transfer & CRO/CMO Support: Facilitating smooth technology transfer and connecting partners with world-class Contract Development and Manufacturing Organizations (CDMOs) or Contract Research Organizations (CROs).

Ongoing Coordination: Maintaining clear communication channels to ensure seamless execution from dossier transfer to commercial distribution.

The Neunco Infrastructure Advantage

Out-licensing success relies heavily on robust operational support. Beyond licensing strategy, Neunco offers an integrated ecosystem that strengthens deal execution:FeatureStrategic Benefit for PartnersEU & US WarehousingGDP-certified facility in the Netherlands and WDA-certified facility in New Jersey ensure compliant sample and batch handling.Integrated CDMO/CMO NetworkSeamless connection to qualified manufacturing partners if tech transfer or scale-up is required post-deal.Clinical Trial SourcingAccess to comparator sourcing and Reference Listed Drugs (RLDs) for necessary bridging studies.

Key Takeaway: Transforming Intellectual Property into Consistent Revenue

Out-licensing should not be an afterthought—it should be a core driver of your commercial growth strategy. With the right strategic partner, your drug formulations and dossiers can generate revenue across multiple international markets simultaneously.

At Neunco, the mission is simple: eliminate entry barriers and connect drug developers with trusted, high-performing global partners.

Ready to Out-License Your Portfolio?

Whether you have ready-to-file dossiers, niche therapeutic formulations, or looking for strategic expansion in international markets, Neunco’s team of experts can guide you through every step of the deal.

Explore Services: Neunco Pharma Licensing Services

 Developing generic drugs and advancing clinical studies require a foundation built on absolute precision, regulatory compliance, and unfailing supply chain integrity. At the heart of every successful bioequivalence study or generic formulation lies a critical component: the Reference Listed Drug (RLD).

Sourcing the exact RLD with specific batch numbers, long shelf-life, and full documentation across global jurisdictions can quickly become a complex logistical hurdle. Choosing the right RLD supplier and comparator sourcing partner is a strategic decision that directly impacts trial timelines, regulatory approvals, and overall development budgets.

Here is a closer look at how strategic RLD sourcing works and why Neunco is trusted globally as a reliable partner for clinical trial supplies and comparator drug sourcing.

What Is Reference Listed Drug (RLD) Sourcing?

A Reference Listed Drug (RLD) is an approved drug product (typically a brand-name therapeutic) identified by regulatory bodies—such as the US FDA or EMA—against which a generic drug candidate is compared. Generic manufacturers must demonstrate that their formulation is bioequivalent to the RLD in active ingredient, dosage form, strength, route of administration, and performance.

Why RLD Sourcing Demands Expert Handling

Unlike standard pharmaceutical purchasing, RLD sourcing for clinical trials and bioequivalence studies requires meeting strict parameters:

Specific Batch & Documentation Needs: Generic developers often require identical batch numbers, certificates of analysis (CoA), sample provenance, or single vs. multi-batch options.

Country-Specific Sourcing: Regulatory guidelines often require sourcing the RLD directly from the target market region (e.g., US-sourced RLD for US FDA submission, EU-sourced for EMA submission).

Shelf Life & Expiry Alignment: Bio-studies require RLDs with extended shelf life to avoid trial disruptions caused by expired comparator supplies midway through testing.

Strict Cold Chain Integrity: Biologics and sensitive active ingredients demand continuous temperature-controlled transportation and validated storage conditions.

How Neunco Simplifies RLD & Comparator Sourcing

At Neunco, we support drug developers, generic pharmaceutical manufacturers, and Contract Research Organizations (CROs) in overcoming these sourcing bottlenecks. We ensure your RLD and comparator supplies are delivered On Time and In Full (OTIF), backed by full traceability and regulatory compliance.

1. Tailored, Customer-Centric Sourcing

Every study has distinct clinical and regulatory requirements. Neunco’s tailored sourcing model accommodates specific requests, including:

Sourcing from targeted geographical markets (EU, USA, South East Asia, Canada, Australia, Japan, Korea, and Latin America).

Specific batch numbers and single or multi-batch lot configurations.

Extended expiry dates to support long-term stability and bio-studies.

Flexible packaging solutions, including one-to-many pack deliveries.

2. EU GDP-Certified & Licensed Global Infrastructure

Storage and logistics failure can compromise an entire trial’s data. Neunco maintains state-of-the-art storage and distribution networks across key regulatory hubs.

From single sample units to high-volume commercial pallet distributions, our certified spaces safeguard product integrity throughout the entire life cycle of your study.

3. Transparent 4-Step Sourcing Process

Neunco employs a structured project management workflow designed to identify risks early and streamline delivery:

1. Understanding: Deep dive into study protocol, target market, batch size, expiry requirements, and regulatory timelines

2. Scrutinizing Global option analysis: Evaluating verified global suppliers, regional regulatory availability, and costs

3. Assessing Risk & route mitigation: Reviewing logistics, cold-chain routes, customs compliance, and batch stability

4. Proposing Execution Plan: Presenting transparent, cost-optimized sourcing strategies with full tracking

4. End-to-End Cold Chain & Last-Mile Logistics

With a Wholesale Distribution Authorization (WDA) and distribution licenses across key markets, Neunco provides temperature-controlled, end-to-end transportation. Real-time status tracking keeps your clinical operations team updated every step of the way.

Key Questions When Evaluating an RLD Supplier

When selecting a partner for clinical trial supplies and RLD sourcing, consider asking:

1. Does the supplier maintain GDP-certified storage in primary markets? Neunco operates EU GDP-certified facilities in the Netherlands and a licensed hub in New Jersey, USA.

2. Can they source country-specific market formulations directly? Neunco’s verified sourcing network spans the US, EU, Asia-Pacific, Latin America, and beyond.

3. Is full batch tracking and temperature logging provided throughout transit? Neunco provides end-to-end traceability and specialized cold-chain logistics for temperature-sensitive drugs.

Partner with Neunco for Your Next Clinical Trial Supply Need

Accelerating generic drug access around the world starts with reliable, compliant, and timely RLD sourcing. Whether you are conducting early-stage bio-studies or large-scale multi-center global clinical trials, Neunco brings the expertise, global reach, and certified infrastructure your program demands.

The journey of bringing a life-saving drug or a high-quality generic formulation to market is notoriously complex. For many pharmaceutical companies, managing everything internally—from raw Active Pharmaceutical Ingredient (API) development to large-scale commercial manufacturing—is risky, expensive, and logistically overwhelming.

Outsourcing has shifted from an operational luxury to a strategic necessity. Whether you need a focused Contract Manufacturing Organization (CMO) to scale a pre-formulated drug, or an integrated Contract Development and Manufacturing Organization (CDMO) to build out synthesis routes using Quality by Design (QbD) principles, finding the right fit is everything.

The endless search for a partner who aligns with your budget, capacity, and regulatory requirements can stall a project before it even starts. That is where Neunco bridges the gap.

The Mid-Market Pitfall: The Search is Harder Than It Looks

Finding a contract manufacturing partner isn't just about looking at a list of certified facilities. The partner you choose determines your regulatory compliance, your market entry timeline, and your ultimate profitability. A bad match can cause:

Capacity constraints that delay product launches.

Regulatory setbacks due to a lack of specific market approvals (like GMP).

Hidden friction during site transfers or pilot-to-commercial scaling.

Neunco acts as a specialized pharmaceutical consultancy. Instead of leaving you to navigate endless pitches and uncertainty, our veterans evaluate your exact project requirements, drug characteristics, and target markets to curate a highly selective group of international-standard manufacturers.

3 Pillars of Tailor-Made Contract Services

At Neunco, we have built an extensive database and a deep global network (spanning the US, Europe, and India) to ensure your drug development process is seamless from inception to distribution. We match you with three distinct classes of specialized partners based on where you are in the product lifecycle:

1. Competent CROs (Contract Research Organizations)

Before manufacturing begins, robust research forms the bedrock of generic drug development. Neunco connects you with premium CROs specializing in:

Basic research and analytical development.

Method and formulation development.

Determining drug purity, structural stability, and chemical modifications.

2. Versatile CMOs (Contract Manufacturing Organizations)

If your drug is already fully developed and pre-formulated, you need an execution partner who takes complete accountability. Our network of verified CMOs adapts to your exact needs, including:

Scaling smoothly from pilot batches to massive commercial production.

Seamless site transfers.

Adherence to strict cost caps and aggressive timelines, all backed by required regulatory approvals (like GMP).

3. Integrated CDMOs (Contract Development & Manufacturing)

For projects requiring both end-to-end development and industrial transposition, Neunco leverages partners operating on a strict dossier-oriented approach. These facilities feature:

Integrated assistance with pre-formulation, stability studies, and validation studies.

Expertise in identifying the most cost-effective and efficient route of synthesis.

Site capacities optimized for successful regulatory filing.

The Neunco Advantage: We maintain a global footprint with EU-GDP certified storage in the Netherlands, a dedicated WDA-approved hub in the United States, and deep manufacturing expertise in India. We don't just find you a manufacturer; we help you streamline your entire global supply chain.

Ready to Streamline Your Product Lifecycle?

Stop spending valuable time on vendor vetting and unpredictable supplier matching. Let our expert consulting team put their research to work for your portfolio, matching your target requirements to elite global production lines.

 For pharmaceutical developers aiming to bring a generic drug or a new therapeutic formulation to life, the road to market approval is built on exact replication and rigorous testing. At the very center of this process sits a critical logistical challenge: sourcing the right Reference Listed Drugs (RLDs) and Comparator Drugs.

With India serving as a global epicentre for generic drug development and clinical research, establishing a flawless supply chain in this region is paramount. However, matching local trial demands with international regulatory compliance requires more than just a standard distributor. It requires a strategic sourcing partner.

Here is how Neunco is transforming the clinical trial supply landscape, helping sponsors seamlessly manage RLD and comparator sourcing both within India and across the globe.

The Baseline: Why RLD & Comparator Sourcing Rules the Trial Life Cycle

In the pharma ecosystem, an RLD acts as the benchmark standard. For a generic manufacturer to prove bioequivalence (meaning the generic version works the exact same way in the body as the original), they must test their formulation side-by-side against the approved brand-name RLD.

Similarly, for sponsors conducting comparative clinical trials for novel therapies, securing a steady, reliable supply of authentic comparator drugs is non-negotiable.

Sourcing these products involves navigating an intricate web of obstacles:

Batch Uniformity: Needing single or multi-batch lots to reduce trial variables.

Shelf Life: Demanding long expiry dates so the product doesn't expire mid-study.

Pedigree and Transparency: Ensuring the supply chain is completely traceable to prove authenticity to regulatory bodies like the FDA, EMA, or CDSCO.

The Neunco Edge: Seamless Sourcing, Engineered for India and Beyond

Neunco addresses these high-stakes requirements by implementing a customer-centric, strategic sourcing model. Rather than treating clinical supply as a simple transaction, Neunco walks with developers through a structured 4-step project management pipeline:

Understanding: Deeply analyzing the exact parameters of your clinical trial or bio-study.

Scrutinizing: Exploring every viable global and local sourcing option to maximize cost-efficiency and compliance.

Assessing: Evaluating regulatory risks, transit routes, and local market nuances to eliminate potential bottlenecks.

Proposing: Delivering tailored sourcing strategies configured to meet your exact timelines.

Tailored to Your Protocol Requirements

Neunco’s global network allows them to accommodate highly specific, strict protocols that standard suppliers often struggle to fulfill. Whether your trial demands sourcing from a specific country of origin, one-to-many pack deliveries, precise batch numbers, or extended shelf lives, their team customizes the acquisition process to preserve the integrity of your clinical data.

Flawless Logistics and State-of-the-Art Global Infrastructure

Securing the drug is only half the battle; maintaining its efficacy from the manufacturer to the testing facility is where true supply chain mastery is tested.

Because many RLDs and comparators are highly sensitive biologic products or chemical entities requiring strict thermal control, Neunco relies on an airtight, validated logistics chain.

World-Class Storage Facilities: Neunco utilizes an EU GDP-certified warehouse in the Netherlands for European operations and a licensed distribution center in New Jersey, USA. Across their verified locations, they boast a combined capacity of over 20,000 pallet positions capable of handling ambient, refrigerated, and frozen conditions.

End-to-End Cold Chain: Utilizing specialized temperature-controlled vehicles and qualified cold-chain shipping partners, Neunco ensures that cold-chain integrity remains intact through the very last mile of distribution.

True Global Footprint: With strategic operational hubs extending from India to the USA, Netherlands, South East Asia, Canada, Australia, Japan, Korea, and Latin America, Neunco handles international cross-border logistics smoothly, bypassing the regulatory friction points that often stall crucial trial phases.

Building the Future of Accessible Medicine

By pairing deep market expertise with a commitment to complete supply chain transparency—featuring active tracking systems so clients can monitor orders in real time—Neunco helps pharmaceutical innovators lower their development costs and accelerate their time-to-market.

 In the modern pharmaceutical industry, bringing a drug from a blueprint to the pharmacy shelf is an incredibly complex journey. One of the most critical elements of this process is the development and production of the Active Pharmaceutical Ingredient (API)—the biologically active component inside a tablet, capsule, or injectable that actually delivers the intended therapeutic effect.

Because manufacturing APIs requires highly specialized infrastructure, extreme chemical precision, and strict adherence to global regulatory frameworks, many pharmaceutical companies choose not to handle this in-house. Instead, they rely on outsourcing. This is where API contract manufacturing—partnering with a Contract Development and Manufacturing Organization (CDMO)—becomes a game-changer.

At Neunco, we specialize in bridge-building within the pharmaceutical ecosystem. As a premier pharmaceutical consultancy with global footprints in the Netherlands, the US, and India, we help drug developers cut through the noise and align with the perfect contract manufacturing partners worldwide.

Let’s dive into why API contract manufacturing is the engine driving pharma growth, the challenges companies face, and how Neunco streamlines the entire process.

The Strategic Benefits of Outsourcing API Production

Developing APIs from scratch requires substantial capital, specialized facilities, and continuous maintenance. By shifting to a contract manufacturing model, pharma innovators unlock distinct competitive advantages:

Significant Cost Efficiency: Setting up capital-intensive research, analysis, and synthesis facilities can easily drain a company's budget. Outsourcing transforms these heavy fixed capital expenses into predictable operational expenses, allowing companies to save on infrastructure while eliminating the costs of managing specialized labs.

Direct Access to Elite Technology & Expertise: Leading CDMOs possess state-of-the-art facilities equipped with advanced automated reactors, precise temperature calibration systems, and rigorous Quality Control (QC) technology. Working with a contract manufacturer lets you deploy these top-tier resources instantly.

Sharper Focus on Core Competencies: When a pharmaceutical company delegates the complex heavy lifting of API synthesis to an external specialist, it frees up internal teams. Your company can focus entirely on its true strengths: drug discovery, clinical trial analysis, marketing, and global retail distribution.

Key Challenges in the API Manufacturing Landscape

While the benefits are undeniable, outsourcing the biological core of your drug product introduces structural hurdles that require careful management:

Protecting Proprietary Data: Safeguarding IP (Intellectual Property) and patented formulations is a massive priority. It is essential to work only with partners who have bulletproof compliance frameworks and legal guardrails to defend your trade secrets.

Maintaining Efficacy & Preventing Impurities: Scaled-up chemical synthesis behaves differently than small-scale laboratory trials. Minor fluctuations in temperature or processing time can trigger unforeseen impurities or compromise the molecular stability of the API. This demands an exceptional, highly trained R&D and analytical team on the manufacturing floor.

Strict Regulatory Oversight: API production must strictly adhere to international guidelines, such as the ICH Q7 standards for Good Manufacturing Practices (GMP). Navigating cross-border compliance, audit readiness, and process validation is incredibly taxing without dedicated regulatory experts.

How Neunco Simplifies the Contract Manufacturing Journey

You don’t have to navigate these complex variables alone. Neunco operates as a trusted strategic consultant, connecting pharmaceutical companies with selective, globally compliant contract manufacturers that tick every single box.

Our team leverages a massive global database and decades of technical experience to analyze your drug profile, target market, and manufacturing volume demands. We conduct exhaustive background research and verify international compliance standards before introducing you to a potential partner, ensuring a seamless, low-risk transition from formulation to full-scale rollout.

Beyond contract manufacturing matchmaking, Neunco offers end-to-end support across the drug lifecycle, including:

Clinical Trial Supply & Comparator Sourcing

Global Distribution via EU-GDP and US-WDA certified facilities

Strategic Sourcing for raw materials and Finished Dosage Forms (FDF)

In-Licensing & Out-Licensing Services

 In the fast-paced world of pharmaceutical development, bringing a new drug to market can feel like navigating an obstacle course. One of the most critical elements of this journey centers around the Active Pharmaceutical Ingredient (API)—the biologically active component of a medicine (whether it’s a tablet, capsule, or injectable) that actually produces the intended therapeutic effect.

Because manufacturing high-quality, compliant APIs requires massive capital investment, niche technical expertise, and rigid regulatory adherence, many pharma companies look outward. This is where API Contract Manufacturing comes into play.

But navigating a global sea of Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) is easier said than done. That is exactly where Neunco steps in to transform your outsourcing journey.

What is API Contract Manufacturing?

Simply put, API contract manufacturing is the strategic outsourcing of your drug substance's development and production to a qualified third-party manufacturer.

Instead of building multi-million dollar facilities and hiring internal teams to manage complex chemical syntheses, pharmaceutical companies partner with dedicated CDMOs. These specialized partners possess the precise instrumentation, temperature-calibration capabilities, and regulatory approvals (like GMP) required to produce safe, high-purity APIs and API intermediates.

Why Pharma Companies Are Outsourcing Their APIs

Outsourcing isn't just about saving a bit of cash; it’s a strategic business move that alters how drugs reach patients.

Drastic Cost Reduction: By eliminating the need to build, maintain, and upgrade massive research and production facilities, companies preserve precious capital.

Scalable Efficiency: Market demands fluctuate. A reliable contract manufacturing partner allows you to easily scale production up or down—whether you need a small clinical pilot batch or large-scale commercial volumes.

Access to World-Class Expertise: Niche therapeutics require specialized hands. Partnering with a CDMO grants you immediate access to top-tier scientists and cutting-edge technologies.

Laser Focus on Core Competencies: When a trusted partner handles complex chemical synthesis and manufacturing, your team is freed up to focus on what they do best: R&D, clinical trials, and commercialized retailing.

The Neunco Difference: We Understand. We Connect. We Curate.

Finding a contract manufacturer is one thing; finding the perfect contract manufacturer that aligns with your specific drug profile, target market, and compliance needs is entirely another.

Neunco operates as an elite pharmaceutical consultancy. We bridge the gap between pharma innovators and vetted, top-tier global contract manufacturers. We do not believe in a one-size-fits-all approach. Instead, our veterans work meticulously to curate ideal partnerships tailored to your unique parameters.

How Neunco Simplifies Your Manufacturing Journey

1. Comprehensive Project Evaluation

Our team sits down with you to deeply analyze your drug substance, targeted therapeutic market, regulatory goals, and strict timeline constraints.

2. Rigorous Database Research

We tap into Neunco's expansive global database of well-known third-party manufacturers, vetting them strictly against international compliance standards.

3. Customized Partner Selection

We select only the contract manufacturers who "tick all the boxes"—ensuring they possess the precise capacity, quality systems (like QbD), and flexibility your project demands.

4. Seamless Matchmaking

We present our thorough findings and transition you smoothly into partnership with your chosen CMO or CDMO, mitigating risk and accelerating your path to market.

Global Footprint, End-to-End Support

Neunco’s capabilities don't stop at contract services. With a highly integrated global network stretching across the USA, the Netherlands, and India, we support your asset across its entire lifecycle—from clinical trial supply sourcing and RLD (Reference Listed Drug) procurement to global distribution and strategic licensing.

When you partner with Neunco, you aren't just finding a manufacturer; you're securing an uninterrupted, compliant supply chain managed by seasoned industry veterans.

Ready to accelerate your market launch? Stop draining time into endless vendor searches and uncertainty. Let Neunco connect you with the precise CRO, CMO, or CDMO your project deserves.

 Bringing a new drug or generic formulation to market is a massive undertaking. Between rigorous clinical trials, complex regulatory compliance, and volatile supply chains, pharmaceutical companies face intense pressure to remain agile and cost-effective.

Because of this, many businesses look toward outsourcing. However, finding a reliable Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) is often easier said than done. The endless search for a partner who can meet your precise capacity requirements, maintain international compliance, and respect your cost caps can quickly stall your product's lifecycle.

That is where a specialized pharmaceutical consultancy makes all the difference. At Neunco, we do not just give you a list of manufacturers—we thoroughly research, carefully curate, and directly connect you with the ideal partner tailored entirely to your drug’s specific profile.

What Does True Pharma Contract Manufacturing Look Like?

At its core, contract manufacturing involves outsourcing specific production tasks—ranging from Active Pharmaceutical Ingredient (API) synthesis to Formulation Development and Finished Dosage Form (FDF) manufacturing—to a qualified third party.

When done correctly, it allows your company to scale up from pilot batches to commercial-scale production seamlessly, without the massive capital expenditure of building your own manufacturing facilities.

How Neunco De-Risks Your Outsourcing Journey

Finding a partner is one thing; finding a partner you can trust with your formulation's integrity is another. Neunco acts as your strategic bridge, leveraging an extensive database and deep industry expertise to align you with best-in-class CROs, CMOs, and CDMOs.

We vet every potential partner against a strict set of criteria to ensure they "tick all the boxes" before we even introduce them to you:

International Compliance Standards: We only work with manufacturers who maintain rigorous international standards (such as strict GMP approvals) tailored to your specific target markets, whether that is the US, the EU, or India.

Flexible Scale & Capacity: Whether you need a site transfer, full-scale commercial manufacturing, or support for niche dosage forms, our network adapts to your exact production size.

Integrated CDMO Expertise: For projects that require integrated assistance, we connect you with CDMOs utilizing Quality by Design (QbD) principles and a dossier-oriented approach. This simplifies your regulatory filings and helps identify the most efficient route of synthesis for your drug.

A Global Ecosystem for the Full Product Lifecycle

Contract manufacturing doesn't happen in a vacuum. A product needs strategic sourcing for its raw ingredients beforehand, and compliant logistics once it leaves the factory floor.

Neunco supports your product at every turn. Beyond contract services, our global footprint features EU-GDP-certified warehousing in the Netherlands and a USA-WDA-certified facility in New Jersey. This allows us to smoothly tie your contract manufacturing needs into a broader strategy that includes clinical trial supply sourcing, comparator drug / RLD sourcing, and global distribution.

 The pharmaceutical landscape is moving faster than ever. For ambitious pharma companies and investors aiming to expand their product lines or break into new territories, traditional drug development presents a major hurdle: it is incredibly slow, resource-heavy, and packed with regulatory risk.

When you are trying to stay ahead of the competition, waiting years for internal R&D to deliver isn't always viable.

This is where in-licensing changes the game. By acquiring ready-to-file or already approved dossiers from a trusted manufacturing partner, you can bypass the early development bottlenecks and secure a rapid, first-mover advantage.

At Neunco, we specialize in bridge-building—connecting companies looking to scale with the perfect out-licensing partners, ready-to-use technologies, and fully compliant dossiers. Here is how strategic in-licensing through a specialized consultancy like Neunco can elevate your business.

The Core Advantages of In-Licensing with Neunco

1. Rapid Pathways to Market (First-Mover Advantage)

Why build from scratch when you can acquire? Neunco enables you to rapidly expand your commercial portfolio by securing approved or ready-to-file dossiers, complete with technology transfers and dossiers ready for bioequivalence (BE) studies. This drastically cuts down your time-to-market, allowing you to maximize profits while your competitors are still stuck in the early development phase.

2. Access to Complex & Rare Therapeutic Areas

Finding data-rich dossiers for niche markets, rare diseases, or complex formulations is notoriously difficult. Neunco maintains a specialized, pre-analyzed global database. Our deep industry contacts allow us to source high-value dossiers for rare therapeutic areas that would otherwise take your team years to research and compile.

3. Global Regulatory Alignment

A dossier is only valuable if it passes strict regulatory scrutiny. Whether your target market is the USA, Europe, Canada, Australia, Japan, or key semi-regulated regions, we ensure the dossiers acquired through our services are meticulously structured to meet the precise guidelines of your destination market.

The Neunco Difference: Beyond the Contract

Finding a partner is one thing; navigating the relationship successfully is another. Neunco provides structured, end-to-end support to ensure your strategic partnership thrives:

Meticulous Due Diligence: We don't just pass along names. Our dedicated team conducts thorough research and rigorous due diligence to match you with a partner that aligns with your operational capabilities and commercial goals.

Comprehensive Project Management: From the initial introductory handshake to the final technology transfer, we provide complete project management. We prioritize absolute transparency, ongoing guidance, and continuous communication.

A World-Class Ecosystem: Our licensing services are seamlessly integrated with our broader network of global contract service providers. Whether you need an elite CRO for hassle-free R&D and tech transfers, or a high-capacity CDMO/CMO to handle outsourced manufacturing, we plug you directly into a verified supply chain.

Ready to Take Your Licensing Game to the Next Level?

Expanding your product lifecycle shouldn’t mean absorbing unmanageable development risks. By working as the central link between global drug manufacturers and commercial investors, Neunco ensures a constant, reliable flow of high-value business for our partners.

Whether your goal is expanding into a new continent, capturing a rare therapeutic market, or securing a steady revenue stream via generic drug acquisition, we have the global network—stretching across the US, EU, Latin America, CIS, Southeast Asia, Africa, and the Middle East—to make it happen.

Let’s unlock the full potential of your pharmaceutical operations.

👉 Explore Neunco’s Licensing Services or connect with our team today at [email protected] to discuss your portfolio strategy.

Bringing a life-saving drug or an innovative healthcare product to market is a journey filled with hurdles. From formulation complexities and strict regulatory compliances to the massive capital required to build a manufacturing plant, the road to commercialization is steep.

For many modern pharmaceutical companies, the solution lies in outsourcing production. However, navigating the vast world of Pharmaceutical Contract Manufacturing is a challenge in itself. How do you find a manufacturing partner that checks every single box?

That is precisely where Neunco steps in. As a premier pharmaceutical consultancy, Neunco acts as the ultimate bridge, connecting pharma brands with elite third-party contract manufacturers that maintain uncompromised international standards.

Why Pharma Contract Manufacturing is the Modern Standard

Setting up a fully functional, compliant manufacturing plant requires millions of dollars in infrastructure and years of regulatory verification. Contract manufacturing flips the script. By handing over production to a specialized third party, your business can unlock incredible strategic advantages:

Massive Cost Efficiency: Capital that would have been tied up in heavy machinery, production facilities, and specialized labor can instead be funneled into Core Research & Development (R&D), branding, and market distribution.

Rapid Scalability: Whether you need a small batch for a niche therapeutic market or a massive rollout to meet global demand, a specialized contract manufacturer can scale production up or down seamlessly.

Direct Access to Cutting-Edge Tech: Rely on partners who utilize advanced manufacturing techniques—such as sophisticated controlled-release systems—without the burden of buying or maintaining the infrastructure yourself.

The Neunco Difference: Taking the Friction Out of Outsourcing

Finding a third-party manufacturer on paper is easy; finding one that perfectly mirrors your brand’s quality metrics, understands your molecule, and satisfies local and international compliance (like WHO-GMP and ISO standards) is exceptionally difficult.

Neunco eliminates the trial-and-error phase from your outsourcing strategy.

Our Mission: To deeply analyze your drug formulation, understand your market targets, and leverage our extensive database to match you with selective, verified contract manufacturers who are flexible, reliable, and compliant.

Here is how Neunco streamlines your path to market:

Deep-Dive Research: Our expert team conducts comprehensive due diligence on potential manufacturing partners, analyzing their track record, financial stability, and technical capabilities before introducing them to you.

Compliance Verification: We ensure that the partners we introduce strictly align with the evolving regulatory frameworks of your target markets, minimizing the risk of costly delays or product recalls.

Smooth Knowledge Transfer: Neunco facilitates a secure, efficient technology transfer process between your team and the manufacturer, ensuring formulas, raw material requirements, and testing parameters are perfectly executed.

Your Next Steps to a Streamlined Supply Chain

In generic drug development and clinical trials, everything rests on a single, critical benchmark: the Reference Listed Drug (RLD) or comparator. Whether you are running complex bioequivalence studies to secure generic approvals or setting up multi-regional clinical trials (MRCTs), your trial’s scientific validity, costs, and timelines depend entirely on the integrity of these sourced reference products.

Yet, finding a secure, transparent, and legally compliant pathway to procure RLDs remains one of the most complex hurdles in the pharmaceutical supply chain. Global regulatory differences, sudden market shortages, and temperature-sensitive logistics mean that traditional sourcing routes frequently fall short.

That is where Neunco steps in. We act as your strategic, customer-centric global sourcing partner, ensuring you receive the exact RLD and comparator requirements On Time and In Full (OTIF).

Why Standard Sourcing Falls Short (And What is at Stake)

Sourcing a comparator is never as simple as placing an order. Sourcing teams regularly face critical supply chain risks that can derail an entire drug program:

Counterfeit and Integrity Risks: Sourcing through unverified open markets puts your study at risk of unauthenticated or sub-quality batches, skewing clinical results.

Documentation Gaps: Missing multi-market paperwork, missing Certificates of Analysis (CoA), or single-lot traceability failure can lead to severe regulatory rejection by agencies like the US FDA or EMA.

Logistical Failures: Temperature spikes during transit can instantly degrade sensitive formulations, ruining expensive trial inventories.

To overcome these barriers, developers require a partner with an established global footprint, rigorous quality gates, and robust localized infrastructure.

The Neunco Advantage: Seamless, Secure, Global Sourcing

Neunco has built an end-to-end framework specifically designed to alleviate procurement friction for pharmaceutical innovators, generic developers, and CROs worldwide.

1. True Global Access and Local Footprints

Rather than relying on localized, middle-tier distributors, Neunco leverages an extensive network across major international hubs. We confidently source and deliver authentic RLDs and comparators worldwide from:

The United States

The European Union

India and South East Asia

Canada, Australia, Japan, Korea, and Latin America

2. End-to-End Certified Logistics and Cold Chain Security

Therapeutic equivalence studies cannot afford compromised product stability. Neunco utilizes qualified logistics partners specializing in validated cold chain and strict temperature-controlled shipments.

Furthermore, our physical infrastructure guarantees full lifecycle safety for your trial assets:

The Netherlands Hub: An EU-GDP (Good Distribution Practice) certified warehouse storage and distribution center in Eindhoven.

USA Hub: A WDA (Wholesale Distribution Authorization) compliant warehouse facility in New Jersey.

Scale Flexibility: Our state-of-the-art warehouses utilize flexible storage configurations—ranging from specialized small bins for niche clinical quantities to massive pallet-sized bins capable of handling hundreds of thousands of packs. We can securely house your RLD requirements over the entire lifecycle of your clinical study.

3. De-Risking Sourcing Through Transparent Project Management

At Neunco, we operate with a strict policy of transparency and openness. We do not just source; we consult. Our experienced project management team follows a rigorous process to optimize your procurement:

1. Risk Assessment: Initial Evaluation.

Our team assesses the regional risks, drug availability, and optimal regulatory sourcing routes to narrow down the safest, most cost-effective fit for your target market.

2. Strategic Sourcing Proposal: Plan Architecture.

We propose recommended strategies and timeline structures that match your specific bioequivalence study or trial phases, focusing on multi-lot optimization and single-source batch consistency.

3. Validated Execution & Storage: Lifecycle Management.

Upon procurement from authorized manufacturers, your products are held in our GDP-certified hubs (EU or USA), allowing for immediate, staggered drop-shipments to trial sites based on your real-time demand.

4. Real-Time Status Tracking: Continuous Visibility.

Through active order management and status tracking, your teams retain complete visibility over documentation clearances and shipment milestones until final delivery.

Build Your Foundation with a Trusted Partner

Developing life-changing therapies demands enough of your focus. Sourcing the benchmarks shouldn't be an operational bottleneck. When you partner with Neunco, you gain more than an RLD supplier; you gain an agile, legally fortified supply network that scales with your product lifecycle.

Streamline your generic drug development and secure your trial timelines today.

In the pharmaceutical sector, bringing a drug from a conceptual molecule to a pharmacy shelf requires navigating an intricate web of chemistry, multi-step synthesis, and strict regulatory pathways. At the very center of this process is the Active Pharmaceutical Ingredient (API)—the biologically active component responsible for delivering the intended therapeutic effect to a patient.

While the API is the absolute backbone of any medication, the infrastructure, specialized equipment, and scientific expertise required to produce it at scale are massive. Building and maintaining these high-tech facilities internally is no longer a viable or cost-effective strategy for most pharmaceutical brands.

This reality has catalyzed a significant industry pivot toward API Contract Manufacturing through Contract Development and Manufacturing Organizations (CDMOs).

What is API Contract Manufacturing?

API contract manufacturing is the strategic outsourcing of the development, testing, and large-scale synthesis of a drug’s active compounds to a specialized third-party manufacturer.

Whether a drug requires a synthetic chemical pathway (often using meticulous crystallization techniques) or a complex biological process (like microbial fermentation using yeast or bacteria), a dedicated contract manufacturer scales production up safely from clinical trial quantities to commercial market volumes.

The Strategic Advantages of Outsourcing API Production

Partnering with the right contract manufacturing organization shifts a brand's operational paradigm from cost-heavy and rigid to asset-light and agile.

1. Drastic Reduction in Capital Expenditure (CapEx)

The financial burden of constructing state-of-the-art cleanrooms, sourcing high-potency compound isolators, and maintaining continuous-flow chemistry equipment can stall a company’s growth. Outsourcing allows pharma companies to completely bypass these overhead costs, turning major capital expenditures into predictable, manageable operational expenses (OpEx).

2. Seamless Regulatory Compliance & Quality Control

API manufacturing is heavily scrutinized by global health authorities. Contract manufacturers operate under stringent Good Manufacturing Practices (GMP). They have established, battle-tested quality assurance teams that routinely handle regulatory audits, trace impurity profiles, and manage documentation—ensuring that every batch meets global purity standards without delaying product launches.

3. Supply Chain Resilience and Scalability

The pharmaceutical supply chain is notoriously volatile. Specialized CDMOs possess robust, pre-vetted networks for raw materials and chemical intermediates. They can quickly pivot to scale production up or down based on market demand or unexpected supply disruptions, preventing devastating drug shortages.

4. Laser Focus on Core Competencies

By delegating the highly technical and asset-intensive manufacturing process to an expert partner, pharmaceutical companies free up vital internal resources. Teams can refocus their energy on what they do best: early-stage molecular research, clinical analysis, and strategic market distribution.

The Million-Dollar Question: How Do You Find the Right Partner?

Outsourcing API production offers immense rewards, but the stakes are high. A minor gap in a partner's quality control or a sudden temperature deviation during manufacturing can compromise an entire batch, leading to millions in lost revenue or regulatory penalties.

When evaluating a contract manufacturing partner, pharma brands must conduct thorough due diligence across several critical pillars:

Technical Arsenal: Do they have the precise equipment required for your specific molecule (e.g., handling high-potency APIs or sterile biologics)?

Track Record: What is their history with regulatory bodies like the FDA or EMA? Have they successfully scaled similar compounds from lab bench to commercial volume?

IP Protection: What stringent protocols do they have in place to safeguard your patented chemical structures and proprietary data?

How Neunco Harmonizes the Sourcing Process

This is exactly where the challenge lies for many pharmaceutical companies: identifying, auditing, and securing a partnership with a manufacturer that ticks every single box.

Neunco acts as a strategic pharmaceutical consultancy, bridging the gap between pharma innovators and elite, international-standard contract manufacturers. Instead of throwing your team into an overwhelming ocean of global suppliers, Neunco leverages a deep database and decades of market expertise to analyze your specific drug formulation, compliance needs, and budget.

By handling the exhaustive research, background vetting, and compliance matching, Neunco delivers clear, highly tailored options. This ensures your API contract manufacturing process transitions smoothly, securely, and efficiently—letting you deliver safe, life-changing medications to the patients who need them most.

Developing a new generic drug or launching a comparative clinical trial is a high-stakes race against time. In the pharmaceutical world, the foundation of every successful bioequivalence (BE) study and generic formulation hinges on a single, critical asset: the Reference Listed Drug (RLD).

For pharmaceutical companies looking to leverage India’s massive clinical trial and generic manufacturing ecosystem, securing these comparator drugs isn't just a logistics hurdle—it is a strategic challenge. Between tight trial timelines, strict global regulatory expectations, and the necessity of complete supply chain integrity, sourcing RLDs demands flawless execution.

Here is a look at what makes RLD sourcing in India uniquely complex, and how Neunco streamlines this process to keep your clinical trials on track, On Time and In Full (OTIF).

The Unique Challenges of RLD Sourcing for Indian Studies

Sourcing a Reference Listed Drug or comparator involves much more than simply purchasing commercial medicine off a shelf. To satisfy regulatory bodies like the USFDA, EMA, or India’s CDSCO, clinical trial sponsors face several strict criteria:

Sourcing from Specific Origin Countries: Regulators often require the RLD to be sourced directly from a specific target market (e.g., the US or EU) to prove true bioequivalence.

Batch and Lot Consistency: Studies frequently require single or multi-batch lots with identical expiration dates to eliminate variables in the trial data.

Extended Shelf Life: Sourcing drugs with long expiry dates is essential to prevent the catastrophic disruption of a trial midway through its lifecycle.

Traceability: Ensuring an unbroken, documented pedigree of the drug from the manufacturer to the site is mandatory to prevent counterfeits and ensure patient safety.

Managing these variables across borders while trying to maintain cost efficiency is where many trial sponsors hit a wall.

How Neunco Fulfills India’s RLD and Comparator Demand

At Neunco, we serve as a vital bridge in the global clinical supply chain. We understand that our stakeholders are scattered globally and have diverse, highly precise requirements. Whether you are an Indian manufacturer developing a generic for global export, or an international sponsor running trials within South Asia, our customer-centric approach eliminates the friction of drug sourcing.

Our robust framework addresses the core needs of modern clinical trials through a meticulous four-step project management lifecycle:

Understanding: We map out your exact trial protocols, specific batch constraints, and target regulatory requirements.

Scrutinizing: We scan global markets to find the most cost-effective and compliant sourcing options.

Assessing: We proactively evaluate logistics risks, customs pathways, and temperature sensitivities to narrow down the safest route.

Proposing: We present a optimized sourcing plan tailored to deliver your exact RLD requirements without surprise delays.

A Flawless Global Infrastructure Built for Compliance

What truly sets Neunco apart is our physical capability to protect your clinical supply chain from end to end. We don’t just broker deals; we manage the assets through certified, state-of-the-art facilities.

Global Footprint, Local Reach: With an EU GDP-certified warehouse in the Netherlands and a certified licensed distribution center in New Jersey, USA, Neunco can seamlessly pull RLDs from the US, Europe, Southeast Asia, Canada, and Latin America, delivering them directly to your trial sites in India and beyond.

Massive, Validated Cold Chain Storage: Together, our verified locations boast over 20,000 pallet positions. We accommodate ambient, refrigerated, and frozen storage conditions, meaning your temperature-sensitive biologics or small molecules retain their efficacy throughout the study lifecycle.

Last-Mile Specialized Logistics: Armed with a Wholesaler Distribution Authorisation (WDA) license, we partner with qualified international cold-chain carriers and utilize specialized temperature-controlled vehicles to ensure the final delivery matches the strict requirements of your trial.

Full Transparency for Peace of Mind

Clinical trials are unpredictable, but your supply chain shouldn't be. Neunco believes in absolute openness. We offer a dedicated status tracking system to our clients, allowing you to actively monitor your order throughout the entire cycle. You will always know exactly where your RLDs are, their temperature status, and their estimated arrival time.

Accelerate Your Drug Development with Neunco

Choosing the wrong supplier can result in scrambled trial timelines, compromised data, and millions in lost revenue.

Neunco checks every box: unmatched regulatory expertise, global reach, massive certified cold-chain storage, and an unwavering commitment to customer-centric execution. We drive innovation by promoting efficient research and manufacturing at every stage of drug development.

Ready to streamline your next clinical trial? Contact the team at Neunco today to discuss your specific Reference Listed Drug (RLD) and comparator sourcing needs.